Abstract
The prognostic role of tumor-infiltrating CD45RO+ memory T lymphocytes (CD45RO+ T cells) in human solid tumors remains controversial. Herein, we conducted a meta-analysis including 25 published studies with 4720 patients identified from PubMed and EBSCO to assess the prognostic impact of tumor-infiltrating CD45RO+ T cells in human solid tumors. We found that CD45RO+ T cell infiltration was significantly associated with improved overall survival (OS) and disease-free survival (DFS) in all types of solid tumors. In stratified analyses, CD45RO+ T cell infiltration significantly improved 1-year, 3-year and 5-year OS in colorectal, gastric and esophageal cancer, but only 5-year OS in hepatocellular carcinoma. And these cells were positively associated with 1-year, 3-year and 5-year DFS in hepatocellular, colorectal and esophageal cancer. In addition, high density of intratumoral CD45RO+ T cells inversely correlated with TNM stage of solid tumor. In conclusion, CD45RO+ memory T lymphocyte infiltration leads to a favorable clinical outcome in solid tumors, implicating that it is a valuable biomarker for prognostic prediction for human solid malignances.
Highlights
Meta-analysis showed that CD45RO+ T cell infiltration was significantly associated with improved 1-year (OR = 2.23, 95% CI 1.69 to 2.94, P = 0.000), 3-year (OR = 2.25, 95% CI 1.80 to 2.82, P = 0.000) and 5-year disease-free survival (DFS) (OR = 2.14, 95% CI 1.63 to 2.79, P = 0.000), but not with 10-year (OR = 1.70, 95% CI 0.92 to 3.15, P = 0.091) DFS in solid tumors (Fig. 4)
We found that CD45RO+ T cell infiltration was significantly inversely correlated with TNM stage (OR = 1.59, 95% CI 1.03 to 2.45, P = 0.038), but not with tumor differentiation (OR = 1.25, 95% CI 0.83 to 1.90, P = 0.285), lymphatic invasion (OR = 1.27, 95% CI 0.74 to 2.19, P = 0.385), or vascular invasion (OR = 1.19, 95% CI 0.92 to 1.54, P = 0.191) of patients (Fig. 6)
In the present meta-analysis, we found that CD45RO+ T cell infiltration had a positive prognostic effect associated with survival in many types of solid tumors especially in CRC, HCC, GC and EC
Summary
We searched PubMed and EBSCO for studies assessing the density of CD45RO+ T cells in tumor tissue and survival in patients with solid tumor from 1996 to January 15th 2017. Inclusion criteria of the meta-analysis were: studies included must have (1) been published as original articles; (2) evaluated human subjects; (3) CD45RO+ T cells in tumor specimens were evaluated by IHC; (4) provided Kaplan – Meier curves of high and low CD45RO+ T cell density with overall survival (OS), and/or disease-free survival (DFS), or relapse-free survival (RFS); (5) published in English. Extracted information included first author’s name, publication year, country, number of patients, median age, gender, Tumor, Lymph Node, Metastasis (TNM) stage, tumor differentiation, time of follow-up, technique used to quantify CD45RO+ T cells, and cut-off value to determine high CD45RO+ T cell density. OS, DFS (or RFS) and clinicopathological data were extracted from the text, tables, or Kaplan – Meier curves for both high and low CD45RO+ T cell density groups. Male/ Female 0/98 0/33 343/161 186/20 76/29 54/20 156/64 260/42 85/20 27/21 28/4 102/8 NR median age (range) (year)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
